Abstract
Liposarcoma (LPS) is a rare malignancy of adipocytic differentiation. According to World Health Organization classification, LPS comprises of four principle subtypes Atypical lipomatous tumor/Well-differentiated liposarcoma (ATL/WDLPS), Dedifferentiated liposarcoma (WDLPS), Myxoid liposarcoma (MLPS), and Pleomorphic liposarcoma (PLPS). Each subtype can develop at any location and shows distinct clinical behavior and treatment sensitivity. ATL/ WDLPS subtype has a higher incidence rate, low recurrence, and is insensitive to radiation and chemotherapy. DDLPS is the focal progression of WDLPS, which is aggressive and highly metastasizing. MLPS is sensitive to radiation and chemotherapy, with a higher recurrence rate and metastasis. PLPS subtype is highly metastasizing, has a poor prognosis, and exhibiting higher recurrence rate. Initial histological analysis provides information for the characterization of LPS subtypes’, further molecular and genetic analysis provides certain subtype specifications, such as gene amplifications and gene fusions. Such molecular genetic alterations will be useful as therapeutic targets in various cancers, including the LPS subtypes. A wide range of novel therapeutic agents based on genetic alterations that aim to target LPS subtypes specifically are under investigation. This review summarizes the LPS subtype classification, their molecular genetic characteristics, and the implications of genetic alterations in therapeutics.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alaggio R, Coffin CM, Weiss SW et al (2009) Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age. Am J Surg Pathol 33:645–658. https://doi.org/10.1097/PAS.0b013e3181963c9c
Anderson WJ, Jo VY (2019) Pleomorphic liposarcoma: updates and current differential diagnosis. Semin Diagn Pathol 36:122–128. https://doi.org/10.1053/j.semdp.2019.02.007
Araujo DM, Druta M, Agulnik M, et al. (2020) SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma". J Clin Oncol 38. https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS11569
Assi T, Kattan J, Rassy E et al (2020) Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. Crit Rev Oncol/Hematol 153:103029. https://doi.org/10.1016/j.critrevonc.2020.103029
Barretina J, Taylor BS, Banerji S et al (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42:715–721. https://doi.org/10.1038/ng.619
Bauer TM, Gounder MM, Weise AM et al (2018) A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). J Clin Oncol 36:11514. https://doi.org/10.1200/JCO.2018.36.15_suppl.11514
Beird HC, Wu C-C, Ingram DR et al (2018) Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Mol Case Stud 4:a002386. https://doi.org/10.1101/mcs.a002386
Boland JM, Colby TV, Folpe AL (2012) Liposarcomas of the mediastinum and thorax: a clinicopathologic and molecular cytogenetic study of 24 cases, emphasizing unusual and diverse histologic features. Am J Surg Pathol 36:1395–1403. https://doi.org/10.1097/PAS.0b013e3182562bc1
Chamberlain F, Benson C, Thway K et al (2021) Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. Future Oncol 17:2659–2670. https://doi.org/10.2217/fon-2020-1092
Cheng H, Dodge J, Mehl E et al (2009) Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Hum Pathol 40:1244–1251. https://doi.org/10.1016/j.humpath.2009.01.011
Chowdhry V, Goldberg S, DeLaney TF et al (2018) Myxoid liposarcoma: treatment outcomes from chemotherapy and radiation therapy. Sarcoma 2018:8029157. https://doi.org/10.1155/2018/8029157
Coindre J-M, Pédeutour F, Aurias A (2010) Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 456:167–179. https://doi.org/10.1007/s00428-009-0815-x
Conyers R, Young S, Thomas DM (2010) Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011:483154. https://doi.org/10.1155/2011/483154
Crozat A, Åman P, Mandahl N et al (1993) Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363:640–644. https://doi.org/10.1038/363640a0
Davidović R, Sopta J, Mandušić V et al (2013) p14 ARF methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma. Med Oncol 30:1–8. https://doi.org/10.1007/s12032-013-0682-9
de Jonge M, de Weger VA, Dickson MA et al (2017) A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. Eur J Cancer 76:144–151. https://doi.org/10.1016/j.ejca.2017.02.005
De Vita A, Mercatali L, Recine F et al (2016) Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. Onco Targets Ther 9:6233–6246. https://doi.org/10.2147/OTT.S112580
Dei Tos AP (2000) Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol 4:252–266. https://doi.org/10.1053/adpa.2000.8133
Demetri GD, Fletcher CD, Mueller E et al (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 96:3951–3956. https://doi.org/10.1073/pnas.96.7.3951
Demetri GD, Von Mehren M, Jones RL et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34:786–793. https://doi.org/10.1200/JCO.2015.62.4734
Demicco EG (2019) Molecular updates in adipocytic neoplasms. Semin Diagn Pathol 36:85–94. https://doi.org/10.1053/j.semdp.2019.02.003
Demicco EG, Torres KE, Ghadimi MP et al (2012) Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol 25:212–221. https://doi.org/10.1038/modpathol.2011.148
Dickson MA, Tap WD, Keohan ML et al (2013) Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 31:2024–2028. https://doi.org/10.1200/JCO.2012.46.5476
Dickson MA, Schwartz GK, Keohan ML et al (2016) Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol 2:937–940. https://doi.org/10.1001/jamaoncol.2016.0264
Dickson MA, Koff A, D’Angelo SP et al (2019) Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. J Clin Oncol 37:11004–11004. https://doi.org/10.1200/JCO.2019.37.15_suppl.11004
Enzinger FM, Winslow DJ (1962) Liposarcoma: a study of 103 cases. Virchows Arch Pathol Anat Physiol Klin Med 335:367–388. https://doi.org/10.1007/BF00957030
Evans HL (1979) Liposarcoma a study of 55 cases with a reassessment of its classification. Am J Surg Pathol 3:507–524. https://doi.org/10.1097/00000478-197912000-00004
Fiore M, Grosso F, Lo Vullo S et al (2007) Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer 109:2522–2531. https://doi.org/10.1002/cncr.22720
Fletcher C, Bridge JA, Hogendoorn PCW, Mertens F (2013) WHO classification of tumours of soft tissue and bone.IARC,France
Forni C, Minuzzo M, Virdis E et al (2009) Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 8:449–457. https://doi.org/10.1158/1535-7163.MCT-08-0848
Funahashi Y, Okamoto K, Adachi Y et al (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105:1334–1342. https://doi.org/10.1111/cas.12488
Gamboa AC, Gronchi A, Cardona K (2020) Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin 70:200–229. https://doi.org/10.3322/caac.21605
Gardner JM, Dandekar M, Thomas D et al (2012) Cutaneous and Subcutaneous Pleomorphic Liposarcoma: A Clinicopathologic Study of 29 Cases With Evaluation of MDM2 Gene Amplification in 26. Am J Surg Pathol 36:1047–1051. https://doi.org/10.1097/PAS.0b013e3182517b96
Garg M, Kanojia D, Mayakonda A et al (2017) Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget 8:7521–7532. https://doi.org/10.18632/oncotarget.13485
Georgantzoglou N, Green D, Lefferts JA et al (2022) A Rare Case of Low-Grade Dedifferentiated Liposarcoma Presenting as a Pharyngeal Polyp: Avoiding a Pitfall With Significant Repercussions. Int J Surg Pathol 30:405–412. https://doi.org/10.1177/10668969211062859
Ghadimi MP, Liu P, Peng T et al (2011) Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer 117:5359–5369. https://doi.org/10.1002/cncr.26195
Göransson M, Andersson MK, Forni C et al (2009) The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-κB target genes by interaction with NFKBIZ. Oncogene 28:270–278. https://doi.org/10.1038/onc.2008.378
Gounder MM, Zer A, Tap WD et al (2016) Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol 34:3166–3174. https://doi.org/10.1200/JCO.2016.67.6346
Gounder MM, Somaiah N, Attia S et al (2018) Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study. J Clin Oncol 36:11512–11512. https://doi.org/10.1200/JCO.2018.36.15_suppl.11512
Haddox CL, Riedel RF (2021) Recent advances in the understanding and management of liposarcoma. Fac Rev 10:1. https://doi.org/10.12703/r/10-1
Haupt YJ, Maya R, Kazaz A et al (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299. https://doi.org/10.1038/387296a0
Hélias-Rodzewicz Z, Pédeutour F, Coindre JM et al (2009) Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma. Genes Chromosomes Cancer 48:943–952. https://doi.org/10.1002/gcc.20696
Hemminger JA, Toland AE, Scharschmidt TJ et al (2014) Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. Mod Pathol 27:1238–1245. https://doi.org/10.1038/modpathol.2013.244
Hornick JL, Bosenberg MW, Mentzel T et al (2004) Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases. Am J Surg Pathol 28:1257–1267. https://doi.org/10.1097/01.pas.0000135524.73447.4a
Hostein I, Pelmus M, Aurias A et al (2004) Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J Pathol 202:95–102. https://doi.org/10.1002/path.1495
Infante JR, Cassier PA, Gerecitano JF et al (2016) A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas Ribociclib (LEE011) in Advanced Solid Tumors or Lymphomas. Clin Cancer Res 22:5696–5705. https://doi.org/10.1158/1078-0432.CCR-16-1248
Italiano A, Bianchini L, Keslair F et al (2008) HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 122:2233–2241. https://doi.org/10.1002/ijc.23380
Italiano A, Bianchini L, Gjernes E et al (2009) Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 15:5696–5703. https://doi.org/10.1158/1078-0432.CCR-08-3185
Jamie S, Colborne S, Hughes CS et al (2019) The FUS-DDIT3 interactome in myxoid liposarcoma. Neoplasia 21:740–751. https://doi.org/10.1016/j.neo.2019.05.004
Kang Y, Horvai AE (2017) p16 immunohistochemistry is less useful than MDM2 and CDK4 to distinguish dedifferentiated liposarcomas from other retroperitoneal mimics. Appl Immunohistochem Mol Morphol 25:58–63. https://doi.org/10.1097/PAI.0000000000000270
Kanojia D, Nagata Y, Garg M et al (2015) Genomic landscape of liposarcoma. Oncotarget 6(40):42429–42444. https://doi.org/10.18632/oncotarget.6464
Keung EZ, Somaiah N (2019) Overview of liposarcomas and their genomic landscape. J Transl Genet Genom 3:8. https://doi.org/10.20517/jtgg.2019.03
Kilpatrick SE, Doyon J, Choong PF et al (1996) The clinicopathologic spectrum of myxoid and round cell liposarcoma: a study of 95 cases. Cancer 77:1450–1458. https://doi.org/10.1002/(SICI)1097-0142(19960415)77:8%3c1450::AID-CNCR5%3e3.0.CO;2-G
Kuroda M, Ishida T, Takanashi M et al (1997) Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 151:735–744
Lee S, Park H, Ha SY et al (2014) CDK4 amplification predicts recurrence of well-differentiated liposarcoma of the abdomen. PLoS ONE 9:e99452. https://doi.org/10.1371/journal.pone.0099452
Lee ATJ, Thway K, Huang PH et al (2018) Clinical and molecular spectrum of liposarcoma. J Clin Oncol 36:151–159. https://doi.org/10.1200/JCO.2017.74.9598
Mariani O, Brennetot C, Coindre J-M et al (2007) JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 11:361–374. https://doi.org/10.1016/j.ccr.2007.02.007
Matthyssens LE, Creytens D, Ceelen WP (2015) Retroperitoneal liposarcoma: current insights in diagnosis and treatment. Front Surg 2:4. https://doi.org/10.3389/fsurg.2015.00004
McCormick D, Mentzel T, Beham A et al (1994) Dedifferentiated liposarcoma clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol 18:1213–1223. https://doi.org/10.1097/00000478-199412000-00004
Mir O, Brodowicz T, Italiano A et al (2016) Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 17:1732–1742. https://doi.org/10.1016/S1470-2045(16)30507-1
Moreau L-C, Turcotte R, Ferguson P et al (2012) Myxoid\round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. Ann Surg Oncol 19:1081–1088. https://doi.org/10.1245/s10434-011-2127-z
Müller CR, Paulsen EB, Noordhuis P et al (2007) Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 121:199–205. https://doi.org/10.1002/ijc.22643
Muratori F, Bettini L, Frenos F et al (2018) Myxoid liposarcoma: prognostic factors and metastatic pattern in a series of 148 patients treated at a single institution. Int J Surg Oncol 2018:8928706. https://doi.org/10.1155/2018/8928706
Narendra S, Valente A, Tull J et al (2011) DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma—assay validation and clinical experience. Diagn Mol Pathol 20:218–224. https://doi.org/10.1097/PDM.0b013e3182107eb9
Narita M, Narita M, Krizhanovsky V et al (2006) A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126:503–514. https://doi.org/10.1016/j.cell.2006.05.052
Nishio J, Iwasaki H, Nabeshima K et al (2011) Cytogenetics and molecular genetics of myxoid soft-tissue sarcomas. Genet Res Int 2011:497148. https://doi.org/10.4061/2011/497148
Ozturk N, Singh I, Mehta A et al (2014) HMGA proteins as modulators of chromatin structure during transcriptional activation. Front Cell Dev Biol 2:5. https://doi.org/10.3389/fcell.2014.00005
Park HK, Kim M, Sung M et al (2018) Status of programmed death-ligand 1 expression in sarcomas. J Transl Med 16:1–11. https://doi.org/10.1186/s12967-018-1658-5
Pilotti S, Della Torre G, Lavarino C et al (1998) Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13–22. J Pathol 185:188–190. https://doi.org/10.1002/(SICI)1096-9896(199806)185:2%3c188::AID-PATH53%3e3.0.CO;2-2
Pishvaian MJ, Marshall JL, Wagner AJ et al (2012) A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 118:5403–5413. https://doi.org/10.1002/cncr.27526
Pollack SM, Jungbluth AA, Hoch BL et al (2012) NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 118:4564–4570. https://doi.org/10.1002/cncr.27446
Ray-Coquard I, Blay JY, Italiano A et al (2012) Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 13:1133–1140. https://doi.org/10.1016/S1470-2045(12)70474-6
Rieker RJ, Weitz J, Lehner B et al (2010) Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. Virchows Arch 456:277–285. https://doi.org/10.1007/s00428-009-0869-9
Saâda-Bouzid E, Burel-Vandenbos F, Ranchère-Vince D et al (2015) Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. Mod Pathol 28:1404–1414. https://doi.org/10.1038/modpathol.2015.96
Sandberg AA (2004) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet 155:1–24. https://doi.org/10.1016/j.cancergencyto.2003.12.018
Sbaraglia M, Bellan E, Dei Tos AP (2020) The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 113:70–84. https://doi.org/10.32074/1591-951X-213
Schöffski P, Chawla S, Maki RG et al (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387:1629–1637. https://doi.org/10.1016/S0140-6736(15)01283-0
Schöffski P, Maki RG, Italiano A, et al. (2015) Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol 33. https://doi.org/10.1200/jco.2015.33.18_suppl.lba10502
Shor AC, Agresta SV, D’amato GZ et al (2008) Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control 15:47–54. https://doi.org/10.1177/107327480801500106
Singer S, Corson JM, Demetri GD et al (1995) Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 221:185–195. https://doi.org/10.1097/00000658-199502000-00009
Singer S, Socci ND, Ambrosini G et al (2007) Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67:6626–6636. https://doi.org/10.1158/0008-5472.CAN-07-0584
Sleijfer S, Ray-Coquard I, Papai Z et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 27:3126–3132. https://doi.org/10.1200/JCO.2008.21.3223
Song Z, Lu L, Gao Z et al (2022) Immunotherapy for liposarcoma: emerging opportunities and challenges. Future Oncol 18:3449–3461. https://doi.org/10.2217/fon-2021-1549
Sreekantaiah C, Karakousis CP, Leong SP et al (1991) Trisomy 8 as a nonrandom secondary change in myxoid liposarcoma. Cancer Genet Cytogenet 51:195–205. https://doi.org/10.1016/0165-4608(91)90132-e
Suarez-Kelly LP, Baldi GG, Gronchi AJEOoP. (2019) Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments. Expert Opin Pharmacother 20:1503–1515. https://doi.org/10.1080/14656566.2019.1618271
Suzuki K, Matsui Y, Endo K et al (2010) Myxoid liposarcoma with EWS–CHOP type 1 fusion gene. Anticancer Res 30:4679–4683
Taylor BS, Barretina J, Socci ND et al (2008) Functional copy-number alterations in cancer. PLoS ONE 3:e3179. https://doi.org/10.1371/journal.pone.0003179
ten Heuvel SE, Hoekstra HJ, van Ginkel RJ et al (2007) Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up. Ann Surg Oncol 14:222–229. https://doi.org/10.1245/s10434-006-9043-7
Tfayli Y, Baydoun A, Naja AS et al (2021) Management of myxoid liposarcoma of the extremity. Oncol Lett 22:1–11. https://doi.org/10.3892/ol.2021.12857
Thelin-Järnum S, Lassen C, Panagopoulos I et al (1999) Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas. Int J Cancer 83:30–33. https://doi.org/10.1002/(sici)1097-0215(19990924)83:1%3c30::aid-ijc6%3e3.0.co;2-4
Thway K (2019) Well-differentiated liposarcoma and dedifferentiated liposarcoma: an updated review. Semin Diagn Pathol 36:112–121. https://doi.org/10.1053/j.semdp.2019.02.006
Thway K, Flora R, Shah C et al (2012) Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol 36:462–469. https://doi.org/10.1097/PAS.0b013e3182417330
Tontonoz P, Singer S, Forman BM et al (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci U S A 94:237–241. https://doi.org/10.1073/pnas.94.1.237
Tyler R, Wanigasooriya K, Taniere P et al (2020) A review of retroperitoneal liposarcoma genomics. Cancer Treat Rev 86:102013. https://doi.org/10.1016/j.ctrv.2020.102013
Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848. https://doi.org/10.1126/science.1092472
Vodanovich DA, Choong PF (2018) Soft-Tissue Sarcomas Indian J Orthop 52:35–44. https://doi.org/10.4103/ortho.IJOrtho_220_17
Von Mehren M, Rankin C, Goldblum JR et al (2012) Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 118:770–776. https://doi.org/10.1002/cncr.26334
Wagner AJ, Banerji U, Mahipal A et al (2017) Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors. J Clin Oncol 35:1304–1311. https://doi.org/10.1200/JCO.2016.70.7117
Willems SM, Schrage YM, Bruijn IH et al (2010) Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option. Mol Cancer 9:1–12. https://doi.org/10.1186/1476-4598-9-257
Yang L, Chen S, Luo P et al (2020) Liposarcoma: advances in cellular and molecular genetics alterations and corresponding clinical treatment. J Cancer 11:100–107. https://doi.org/10.7150/jca.36380
Acknowledgements
None
Funding
This work was supported by funding received from Kerala State Council for Science, Technology and Environment (KSCSTE), Government of Kerala, India (Project no 332/2021/KSCSTE).
Author information
Authors and Affiliations
Contributions
A.M.S.: Conceptualization, Original Draft Preparation: conceived and drafted the original manuscript. C.K.: Review, and Editing. R.V.B.: Review, and Editing. L.S.: Conceptualization and oversight; final approval of the version to be submitted.
All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical approval
Not applicable.
Competing interest
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
M.S, A., K, C., Bhargavan, R.V. et al. An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies. J Mol Histol 55, 227–240 (2024). https://doi.org/10.1007/s10735-024-10195-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10735-024-10195-4